These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 24099875)

  • 1. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective chikungunya virus-like particle vaccine produced in insect cells.
    Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
    PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
    Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
    Front Immunol; 2021; 12():655743. PubMed ID: 33868299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
    Arévalo MT; Huang Y; Jones CA; Ross TM
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
    Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
    J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
    Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
    Front Immunol; 2020; 11():591885. PubMed ID: 33224148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus.
    Basu R; Zhai L; Rosso B; Tumban E
    Vaccine; 2020 Mar; 38(11):2542-2550. PubMed ID: 32044164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.
    van den Doel P; Volz A; Roose JM; Sewbalaksing VD; Pijlman GP; van Middelkoop I; Duiverman V; van de Wetering E; Sutter G; Osterhaus AD; Martina BE
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3101. PubMed ID: 25188230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
    Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
    J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
    Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
    J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
    Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells.
    Metz SW; Pijlman GP
    Methods Mol Biol; 2016; 1426():297-309. PubMed ID: 27233282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior protection conferred by inactivated whole virus vaccine over subunit and DNA vaccines against salmonid alphavirus infection in Atlantic salmon (Salmo salar L.).
    Xu C; Mutoloki S; Evensen Ø
    Vaccine; 2012 Jun; 30(26):3918-28. PubMed ID: 22504037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
    Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
    PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
    Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.